ALCESTER, England, February 6, 2017 /PRNewswire/ --
Quanta Dialysis TechnologiesLtd ("Quanta" or the "Company"), a medical device company providing innovative haemodialysis solutions for the clinic and the home, today announces it has appointed Dr Sandip Mitra to its Medical Advisory Board.
Sandip qualified as a doctor in India and has since received speciality training in nephrology in Stevenage, Oxford and Manchester. Sandip has written extensive research on uraemia and dialytic therapies at University College London, Royal Free Medical School. He was previously Senior Research Fellow UCL, Royal Free Hospitals and Lister Hospital in Hertfordshire. He has won multiple awards for his work, research and innovation, including the Health Service Top Innovator Award in 2013, National Award Winner of the NHS Innovation Challenge and NICE excellence Award in 2011 as well as the British Journal of Renal Medicine Awards in 2010.
John E. Milad, Chief Executive Officer of Quanta, said "We are delighted that Sandip has chosen to join our Medical Advisory Board. He is a world-leading nephrologist and understands that innovation is a powerful enabler for improving patient outcomes and experiences in dialysis, whilst achieving better value for money. Over the course of the last decade, Dr Mitra has been an effective champion of home dialysis and I look forward to working with him as we expand the use of SC+ within the NHS."
For more information about Quanta, please contact:
Quanta John E. Milad, T: +44 (0)1789 400043 Chief Executive Officer E: email@example.com Consilium Strategic Communications T: +44 (0)203 709 5708 Julia Wilson / Matthew Neal / Lindsey Neville E: firstname.lastname@example.org
About SC+ SC+ supports patients across the continuum of care from the clinic to the home. It is the only easy-to-use, compact, haemodialysis system offering high performance comparable to conventional devices and compatible with traditional treatment regimens used in-centre. The technology behind SC+ is based on an innovative and unique design that incorporates all fluid management activities onto a single-use disposable cartridge. This cartridge-based design is intended to reduce downtime, simplify treatment complexity and reduce the risk of contamination. SC+ has regulatory approval in Europe (CE Mark) and is currently being used to treat patients in the UK. About Quanta Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use in the clinic and the home. The Company's lead product SC+ provides performance, flexibility and convenience to empower dialysis patients to regain control of their lives. Founded in 2008 and based in Alcester, UK, Quanta has attracted funding from a group of leading investors including: Stage Capital/NBGI Ventures, Wellington Partners, Seroba, b-to-v Partners, ALIAD, Seventure Partners and Kuwait Life Sciences Company, as well as IMI plc. For more information, please visit: http://www.quantadt.com.
Subscribe to our Free Newsletters!
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Inborn errors of metabolism are genetic disorders that hamper the body''s metabolism resulting in ...
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...View All